SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-069901
Filing Date
2018-11-26 16:30:42
Period of Report
Item 1.01: Entry into a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-40620_18k.htm 8-K 28246
2 EX-10.1 a18-40620_1ex10d1.htm EX-10.1 114908
  Complete submission text file 0001104659-18-069901.txt   144812
Mailing Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 212-297-0020
SYNERGY PHARMACEUTICALS, INC. (Filer) CIK: 0001347613 (see all company filings)

IRS No.: 330505269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35268 | Film No.: 181201158
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences